Home LiteratureArticle Details
PMID: 14571738 Published · ppublish English Journal Article

Recurrence patterns after curative resection of colorectal cancer in patients followed for a minimum of ten years.

Hepato-gastroenterology ·Vol. 50 ·No. 53 ·2003-00-00 ·Pages 1362-6

Sadahiro S, Suzuki T, Ishikawa K, Nakamura T, Tanaka Y, Masuda T, Mukoyama S, Yasuda S, Tajima T, Makuuchi H, Murayama C

Abstract

To investigate the recurrence patterns and interval from initial surgery in patients with curatively resected colorectal cancer followed for a minimum of 10 years. We retrospectively reviewed 418 patients who had undergone curative resection for colon cancer (n = 246) or rectal cancer (n = 169). Follow-up periods ranged from 10 to 23 years. Main outcome measures were interval until recurrence, site of first recurrence, and influence of adjuvant chemotherapy. 26 (6%) had been lost to follow-up by 10 years and 143 (34%) had died. The most common site of recurrence was liver in colon cancer and locoregional in rectal cancer. The cumulative recurrence rate in colon cancer was 100% at 4 years. In rectal cancer, it was 89% at 5 years, 98% at 7 years and 100% at 10 years. The interval until recurrence was longer in rectal cancer (26.0 +/- 24.2 months) than in colon cancer (17.1 +/- 11.0 months) (p = 0.03). It was also longer in patients receiving than in those not receiving adjuvant chemotherapy (p < 0.01). The interval until lung metastasis was longer than that until liver metastasis in colon cancer (p = 0.04), and longer than that until locoregional recurrence in rectal cancer (p = 0.03). The interval until recurrence in the colon cancer was shorter for stage III than for stage II (p = 0.02). Surveillance for recurrences, particularly for relapses in the liver and lung, should be performed for at least 4 years in colon cancer patients. Patients with rectal cancer should be followed for a longer period than those with colon cancer, focusing on locoregional, liver and lung recurrence. It is particularly noteworthy that adjuvant chemotherapy may prolong the interval until recurrence and the interval until lung metastasis is relatively longer.

MeSH Terms
Chemotherapy, Adjuvant Colonic Neoplasms/drug therapy,mortality,pathology,surgery Follow-Up Studies Humans Liver Neoplasms/secondary Lung Neoplasms/secondary Neoplasm Recurrence, Local/epidemiology,prevention & control Neoplasm Staging Rectal Neoplasms/drug therapy,mortality,pathology,surgery Retrospective Studies Survival Analysis Time Factors
Authors & Affiliations
11 authors, click to expand affiliations / ORCID
Sadahiro Sotaro
Department of Surgery, Tokai University School of Medicine, Bohseidai, Isehara, Kanagawa, 259-1193, Japan. sadahiro@is.icc.u-tokai.ac.jp
Suzuki Toshiyuki
Ishikawa Kenji
Nakamura Tomoki
Tanaka Yoichi
Masuda Takahisa
Mukoyama Sayuri
Yasuda Seiei
Tajima Tomoo
Makuuchi Hiroyasu
Murayama Chieko
Article Info
Journal
Hepato-gastroenterology
Abbr.
Hepatogastroenterology
ISSN
0172-6390
Published
2003-00-00
Pages
1362-6
Language
English
Region
Greece
NLM ID
8007849
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com